EMA CHMP Recommends 12 Medicines for Approval

The European Medicines Agency (EMA) announced that its Committee for Medicinal Products for Human Use (CHMP) recommended 12 new medicines for marketing authorisation and six for extension of therapeutic indications during its February 2026 meeting. Key recommendations include mCombriax, a combined mRNA vaccine for COVID-19 and influenza; Ojemda for paediatric low-grade glioma; and Onerji for advanced Parkinson's disease. The CHMP also adopted positive opinions for several biosimilar medicines, including insulins, etanercept, pertuzumab, and tocilizumab.

These recommendations signify potential new treatment options for patients across the EU. Pharmaceutical companies and drug manufacturers should monitor the subsequent marketing authorisation decisions by the European Commission. While these are recommendations, they represent a significant step towards new product availability, impacting clinical practice and patient access to innovative therapies. No immediate compliance actions are required for regulated entities based solely on these recommendations, but strategic planning for new product integration may be warranted.